Subscribe To
EMMLF / Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
EMMLF News
By InvestorPlace
August 1, 2023
Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
OKYO Pharma (NASDAQ: OKYO ) stock is falling on Tuesday even after the biopharmaceutical company withdrew a public offering. According to a press rel more_horizontal
By Proactive Investors
July 28, 2023
OKYO Pharma inks collaboration with Tufts Medical Center
OKYO Pharma Ltd (NASDAQ:OKYO) has revealed a new partnership with Tufts Medical Center to conduct an open-label clinical trial to assess the efficacy more_horizontal
By Proactive Investors
June 6, 2023
OKYO Pharma begins OK-101 phase 2 dosing
OKYO Pharma said patients are being dosed in a randomise portion of a phase 2 trial for its OK-101 drug to treat dry eye disease (DED). The ophthalmo more_horizontal
By Proactive Investors
December 22, 2022
OKYO Pharma receives US FDA license to start Phase 2 study
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said its dry eye disease treatment has received its investigational new drug (IND) application from the US Fo more_horizontal
By Proactive Investors
May 20, 2022
Okyo Pharma successfully closes US$2.5mln US fundraise
Okyo Pharma Ltd (LSE:OKYO, OTCQB:EMMLF) has confirmed it has successfully closed a US$2.5mln US fundraiser. The group, which is developing a treatment more_horizontal
By Proactive Investors
May 17, 2022
OKYO Pharma to raise US$2.5mln in the US
OKYO Pharma Ltd, the specialist in inflammatory dry eye disease, said it is raising a gross US$2.5mln by issuing American depositary shares priced at more_horizontal
By Seeking Alpha
March 24, 2022
OKYO Pharma: Developer Of Next Generation Ocular Therapeutics
OKYO Pharma: Developer Of Next Generation Ocular Therapeutics more_horizontal
By Proactive Investors
February 23, 2022
OKYO Pharma receives US patent for dry eye disease drug covering neuropathic pain
OKYO Pharma Ltd said it has been issued a US patent for its dry eye disease candidate (DED) OK-101. The key claim in the application covered the drug more_horizontal